HumaScan downgrades payment to Scantek:
This article was originally published in Clinica
Executive Summary
Following the FDA's warning letter to HumaScan last month over its BreastAlert differential temperature sensor for use as an adjunct in breast cancer detection, the company has announced changes to its US licensing deal with Scantek Medical. Scantek licenses the technology to HumaScan. The new arrangements include elimination of $450,000 in royalties due in the first two years of production, a further cancellation of $200,000 in connection with acquiring production machinery and a reduction of $375,000 in cash licence fees.